Clinical trial
An Exploratory, Randomised, Double-blind, Multicentre, Placebo-controlled Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
NCT06465303 is registered in ClinicalTrials.gov with ResoTher Pharma as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory, Randomised, Double-blind, Multicentre, Placebo-controlled Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
- Lead sponsor
- ResoTher Pharma
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 16, 2024
- Completion date
- July 2, 2026
- Enrollment
- 66 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.